eligibility_summary
Men ≥18 with high‑risk localized prostate adenocarcinoma (T1c–T3b, N0/M0, PSMA N1 allowed ≤3 LNs ≤1 cm), ≥3 positive cores (incl ≥4+3 with high‑risk feature or Gleason ≥8), radical prostatectomy scheduled, ECOG 0–1/KPS ≥70, adequate labs, consent and barrier contraception. Exclude CT N1/M1 beyond above, non‑adenocarcinoma, prior PCa therapy, immunotherapy/experimental drugs, systemic steroids, autoimmune needing IS, recent cancer, uncontrolled illness, active HIV/HBV/HCV (unless cured).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Enoblituzumab (MGA271) vs standard-of-care radical prostatectomy. Enoblituzumab is an Fc‑engineered, humanized IgG1 monoclonal antibody targeting B7‑H3 (CD276), given neoadjuvantly (15 mg/kg IV q2w for 12 weeks). Mechanism: binds B7‑H3 overexpressed on prostate tumor cells and tumor-associated stroma/vasculature, engages Fcγ receptors to drive ADCC/ADCP by NK cells and macrophages (possible CDC) and may alleviate B7‑H3–mediated immunosuppression to enhance T‑cell activity. Targets/pathways: B7‑H3 immune checkpoint axis, FcγR effector pathways (NK cells, macrophages), downstream antitumor T‑cell responses. Comparator: surgery alone.